a few key differences here that you have highlighted iwell
insto investment = why share price appreciation is great in one stock and not in the other
end market potential and result strength are the next . The market (% insto holding) is just not willing to take a big punt on neu on weak results despite the fact there is no other drugs available for retts. Unfortunately this will not see true value until phase 3 is done. Very frustrating stock when you see others like Dxb par opt absolutely smashing it .
Ann: Neuren to capture substantially greater value after Phase 3, page-87
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |